ZIVO Bioscience, Inc. (ZIVO): Marketing Mix Analysis [Dec-2025 Updated]

You're looking at ZIVO Bioscience, Inc. right at that tricky inflection point: moving from the lab bench to real-world sales in late 2025. Honestly, the financials show it's still R&D-heavy, with trailing revenue at just $209K, but the strategy is clear: proprietary, antibiotic-free algae ingredients sold direct and licensed out. We need to see if their contract manufacturing scale-up and focus on scientific proof can justify the premium pricing they'll need to hit that projected $428.000K revenue by Q4. Let's break down the four P's to see if the plan is sound.

ZIVO Bioscience, Inc. (ZIVO) - Marketing Mix: Product

You're looking at the core offering of ZIVO Bioscience, Inc., which is centered on its proprietary algal platform. This platform is the source for non-GMO, plant-based bioactive ingredients, built upon a portfolio of optimized freshwater algae strains. This gives you a new, plant-based, non-GMO, antibiotic-free, sustainable source of protein, fiber and micronutrients with added health benefits. The company's intellectual property portfolio includes these proprietary algal and bacterial strains, along with the associated production and cultivation techniques. This technology is being directed toward both human nutrition and animal health applications.

The initial human functional food product is Zivolife™ dried green algae powder. Commercial shipments of this product started in June 2023, aimed squarely at the North American green powder food market. Zivolife™ is marketed as a whole-food supplement, being natural, non-GMO, and a source of plant-based protein, naturally occurring beta glucan and fiber. It also delivers essential amino acids, polyphenols, iron, potassium and vitamins A, E and B12. It's tested to be shelf stable for up to two years, and its functional claims support digestive and gut health and help to support a healthy immune system.

The company's product focus in the animal health space is heavily weighted toward providing antibiotic-free, immune-modulating solutions. This directly addresses the global challenge of reducing antibiotic use in agriculture, aiming for cost parity without sacrificing animal productivity. For instance, formulations for dairy cows are designed to promote a healthy immune response to bovine mastitis, while poultry formulations aim to boost productivity and digestive efficiency. The company is actively pursuing several therapeutic and nutritional indications, which you can see detailed below.

The pipeline development is progressing across several key areas, with specific studies underway in collaboration with a leading global animal health company. For example, a 42-day study focused on coccidiosis in poultry is designed to confirm previously demonstrated effects of ZIVO's compound when co-administered with a vaccine. This trial is intended to support the regulatory approval process of the USDA's Center for Veterinary Biologics. Anyway, the company's R&D efforts are contingent on securing additional funding to advance these candidates.

Here's a quick look at the key product pipeline targets and their status or intended application:

• The proprietary algal biomass has a self-affirmed GRAS designation, updated in May 2023, for use as an ingredient in foods and beverages, allowing a consumption limit of up to nine grams per day.
• The production scale-up is a major focus, with plans to complete the build-out at Alimenta Algae in late 2025, targeting a capability to produce roughly 100,000 kg per year.
• Preliminary independent biochemical analysis showed ZIVO's algae had, on average, nearly double the activity of SOD compared to a competing algae-based product.
• The offtake agreement for Zivolife™ includes a commitment from ZWorldwide, Inc. to purchase at least 24,000 kg per year for a minimum of five years, subject to contingencies.
• As of September 30, 2025, ZIVO Bioscience reported a trailing 12-month revenue of $209K.

To give you a clearer picture of the product portfolio and its supporting metrics as of late 2025, here is a summary:

The company's pipeline applications are diverse, spanning both animal and human health sectors, leveraging the core bioactive compounds derived from the algae. The focus on immune-modulating solutions is key to their value proposition in animal agriculture.

If you look at the recent financial context as of early December 2025, the stock price was trading around $10.35, with a market capitalization of approximately $40.25M. The net loss for the nine months ended September 30, 2025, was $6,884,474. Finance: draft 13-week cash view by Friday.

ZIVO Bioscience, Inc. (ZIVO) - Marketing Mix: Place

You're looking at how ZIVO Bioscience, Inc. gets its proprietary algal biomass from the farm to the customer. Place, or distribution, is all about making sure the product is where the consumer needs it, when they need it. For ZIVO Bioscience, Inc., this involves a tightly controlled, multi-channel approach centered on scaling production first.

The foundation of the Place strategy rests on the contract manufacturing scale-up. ZIVO Bioscience, Inc. is collaborating with Alimenta Algae SAC in Peru to repurpose their microalgae facility. This facility is anticipated to be fully operational in the second or third quarter of 2025, targeting a final capacity of up to 100,000 kilograms of dried product per year by late 2025. Honestly, getting that supply chain locked in is the critical first step before any real distribution push can happen.

The primary commercial channel for the branded Zivolife™ product is clearly defined. ZWorldwide, Inc., an independent distributor based in Miami, Florida, holds the exclusive rights for North American distribution. This relationship dictates the initial market entry focus, which is the North American green powder food segment. ZWorldwide manages the branded product sales, which commenced in June 2023, and this activity generated Total Revenue of $157,220 for the fiscal year ended December 31, 2024. That revenue was driven by product volumes, even with lower selling prices that year.

Distribution is executed through two main routes. First, ZWorldwide, Inc. functions as a direct-to-consumer marketing company, actively retailing the Zivolife™ product directly to end-users via its online platform, www.zivo.life. Second, the B2B channel is being developed through licensing ZIVO Bioscience, Inc.'s internally developed intellectual property, including proprietary algae cultures and bioactive molecules, to major animal and human health manufacturers. As of the September 10, 2025, update, ZIVO Bioscience, Inc. is noted as being in pre-revenue status specifically regarding the monetization of this licensing IP, though they are actively pursuing deal terms involving upfront payments, milestones, and royalties for therapeutic candidates like the coccidiosis treatment.

Here's a quick look at the key distribution and capacity metrics as the company targets full operational scale:

The distribution structure relies heavily on this partnership model:

• Contract manufacturing with Alimenta Algae in Peru scales to 100,000 kg capacity by late 2025.
• ZWorldwide, Inc. acts as the independent distributor for branded products in North America.
• Direct-to-Consumer (DTC) sales are managed via the Zivolife™ online platform.
• B2B channel involves licensing ingredients to major animal and human health manufacturers.
• Primary market entry focus is the North American green powder food segment.

If onboarding takes longer than expected for new B2B licensing partners, revenue diversification will be delayed. Finance: draft 13-week cash view by Friday.

ZIVO Bioscience, Inc. (ZIVO) - Marketing Mix: Promotion

You're looking at how ZIVO Bioscience, Inc. communicates its value proposition to investors and the market as of late 2025. Investor relations is clearly a primary promotional channel, evidenced by management presenting at The Microcap Conference 2025 held January 28-30, 2025, in Atlantic City, N.J.. Specifically, the corporate presentation was scheduled for Thursday, January 30, 2025, at 2:30 PM Eastern Time. This event was designed for management to engage in one-on-one meetings with institutional and individual investors.

The company used direct communication to reinforce its narrative. The CEO Letter to Shareholders issued on September 10, 2025, framed the preceding year as one of the most pivotal in the company's history. This letter highlighted active discussions with major nutraceutical clients, anticipating material increases in human health revenues. Furthermore, it disclosed that members of the Board and the CEO personally invested in the company, signaling internal confidence.

Scientific validation forms a core part of the promotional material, disseminated via press releases detailing study outcomes. For instance, results from a 42-day confirmatory study on coccidiosis showed statistically significant improvements in growth performance, specifically the Feed Conversion Ratio (FCR), when ZIVO's product was used alongside an anticoccidial ionophore or vaccination, compared to controls receiving only the ionophore or vaccine. The improvement in FCR was reported as not statistically different from the market-leading commercial ionophore. This positions the compound within the $1.5 billion coccidiosis market.

The June 2025 strategic partnership was a major promotional catalyst. On June 20, 2025, ZIVO Bioscience announced the execution of two agreements with a leading global animal health company to advance its poultry compounds. The research under these agreements is fully funded by the partner. The first agreement initiated a 42-day study focused on coccidiosis, while the second addresses a model of various viral diseases.

The core messaging consistently drives toward urgent global demand drivers. The promotional narrative centers on offering 'antibiotic-free' and 'sustainable' solutions. The animal health initiatives specifically target the urgent global need to reduce antibiotic dependence while maintaining or enhancing animal health and productivity, aiming for cost parity.

Here is a quick view of the key promotional activities and associated data points:

The company's promotional strategy leans heavily on validating its science through third-party studies and leveraging major partnerships to convey credibility. You see this focus on quantifiable scientific outcomes rather than broad advertising spend.

• Messaging emphasizes 'antibiotic-free' solutions.
• Messaging emphasizes 'sustainable' solutions.
• Animal health goal: Reducing antibiotic use at cost parity.
• Coccidiosis study confirmed statistical improvement in FCR.
• Management engaged in one-on-one meetings with investors at the January 2025 conference.

ZIVO Bioscience, Inc. (ZIVO) - Marketing Mix: Price

You're looking at the pricing structure for ZIVO Bioscience, Inc. (ZIVO) as the company navigates its R&D phase toward broader commercialization. Honestly, the current revenue profile dictates a very cautious approach to pricing, as the financial reality shows limited sales volume right now.

Trailing twelve-month revenue as of Q3 2025 is low at $209K, reflecting an R&D-stage company. This minimal top-line figure means pricing decisions are currently more about securing initial adoption and validating market acceptance than maximizing immediate profit margins.

Q3 2025 actual revenue was $65.63K, indicating nascent commercial sales volume. To give you a fuller picture of the scale, the revenue for the first nine months of 2025 totaled $119,025. This low revenue contrasts sharply with the operational burn rate; for instance, the net loss for Q3 2025 stood at $(1,033,056).

Here's a quick look at how the revenue is tracking against expectations, which informs any pricing flexibility you might see:

The strategy for the B2B animal health segment is clearly defined by the market need for alternatives. Pricing strategy for B2B animal health aims for cost parity with existing non-antibiotic solutions. This makes sense; you can't ask a major producer to pay a premium for a new, unproven solution when they are trying to reduce costs by moving away from antibiotics.

Conversely, the consumer-facing side likely operates under a different model. Zivolife™ consumer product likely carries a premium price point typical of specialty nutraceuticals. This suggests a value-based pricing approach, relying on perceived health benefits rather than direct cost comparison.

The company's current financial position definitely constrains aggressive pricing moves, though future projections offer optimism. Consider the balance sheet context:

• Cash on hand as of September 30, 2025, was only $57,222.
• Total Current Liabilities were significantly higher at $3,614,268.
• The stock price as of December 2, 2025, was $10.35.

Future revenue is projected to grow materially, with a 2025 Q4 consensus forecast of $428.000K. This expected jump suggests that if commercial partnerships materialize as planned, the pricing power for the B2B segment might shift from cost parity toward value capture, especially if they can demonstrate superior efficacy over other non-antibiotic options.

The core of the pricing strategy revolves around these two distinct market approaches:

• B2B Animal Health: Target cost parity against current non-antibiotic options.
• Consumer Nutraceuticals: Command a premium price based on specialty ingredient value.

Finance: draft 13-week cash view by Friday.